{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:43Z","timestamp":1761872143878,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:50:25Z","timestamp":1670273425000},"page":"e182-e189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed\/Refractory Multiple Myeloma: A Single-Institution Experience"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah M.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-9846","authenticated-orcid":false,"given":"Michael","family":"Ozga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-9443","authenticated-orcid":false,"given":"Harshil","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-7987","authenticated-orcid":false,"given":"Muhammad S.","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1433-3677","authenticated-orcid":false,"given":"Sadia","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-7099","authenticated-orcid":false,"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.001_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.001_bib0002","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.12.001_bib0003","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.001_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.001_bib0007","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.001_bib0008","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2003-01-0073","article-title":"Transplantation for multiple myeloma: who, when, how often?","volume":"102","author":"Blade","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.001_bib0009","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: a systematic review and critical appraisal of published studies","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","author":"Richardson","year":"2022","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.clml.2022.12.001_bib0011","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2022.12.001_bib0012","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.bbmt.2018.12.002","article-title":"The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma","volume":"25","author":"Hagen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2022.12.001_bib0013","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/bmt.2017.160","article-title":"Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents","volume":"52","author":"Tremblay","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2022.12.001_bib0014","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bbmt.2014.11.677","article-title":"Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma","volume":"21","author":"Singh Abbi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2022.12.001_bib0015","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3109\/10428194.2013.773998","article-title":"Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation","volume":"54","author":"Auner","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2022.12.001_bib0016","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bmt.2012.183","article-title":"Second auto-SCT for treatment of relapsed multiple myeloma","volume":"48","author":"Gonsalves","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2022.12.001_bib0017","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbmt.2012.11.013","article-title":"Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma","volume":"19","author":"Lemieux","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.12.001_bib0018","doi-asserted-by":"crossref","unstructured":"Sellner L, Heiss C, Benner A, et\u00a0al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 2013; 119(13):2438-46. doi: 10.1002\/cncr.28104.","DOI":"10.1002\/cncr.28104"},{"issue":"2","key":"10.1016\/j.clml.2022.12.001_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2012.02867.x","article-title":"Relapsed multiple myeloma: who benefits from salvage autografts?","volume":"43","author":"Chow","year":"2013","journal-title":"Intern Med J."},{"issue":"14","key":"10.1016\/j.clml.2022.12.001_bib0020","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1002\/cncr.26662","article-title":"Durable remission with salvage second autotransplants in patients with multiple myeloma","volume":"118","author":"Shah","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2022.12.001_bib0021","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2011.01634.x","article-title":"Melphalan 100 mg\/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation","volume":"87","author":"Blimark","year":"2011","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2022.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3109\/10428194.2011.575967","article-title":"Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation","volume":"52","author":"Fenk","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2022.12.001_bib0023","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2022.12.001_bib0024","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428190903085936","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2022.12.001_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2022.12.001_bib0026","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.12.001_bib0027","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.clml.2022.12.001_bib0028","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.001_bib0029","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/bmt.2012.164","article-title":"Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT","volume":"48","author":"Yhim","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.12.001_bib0030","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.12.001_bib0031","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:04Z","timestamp":1761871264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017463"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed\/Refractory Multiple Myeloma: A Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}